Endometrial carcinomas with significant mucinous differentiation associated with higher frequency of K-ras mutations: A morphologic and molecular correlation study

International Journal of Gynecological Cancer

Volumn 23, Issue 7, 2013, Pages 1231-1236

  Xiong, Jinjun ^a   He, Mai ^a   Jackson, Cynthia ^a   Ou, Joyce J ^a   Sung, C James ^a   Breese, Virgina ^a   Steinhoff, Margaret M ^a   Quddus, M Ruhul ^a   Tejada Berges, Trevor ^a   Lawrence, W Dwayne ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

DNA sequencing; Endometrial carcinoma; K ras mutation; Mucinous differentiation

Indexed keywords

K RAS PROTEIN;

ARTICLE; CAPILLARY ELECTROPHORESIS; CELL DIFFERENTIATION; CLINICAL FEATURE; COLLOID CARCINOMA; CORRELATIONAL STUDY; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; FEMALE; GENE SEQUENCE; HUMAN; MAJOR CLINICAL STUDY; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ADENOCARCINOMA, MUCINOUS; CELL DIFFERENTIATION; CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MUTATION; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS;

EID: 84884517037     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e31829ea82f     Document Type: Article

References (25)

1. Lax SF. Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Arch. 2004;444:213-223.
2. Hecht JL, Mutter GL. Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol. 2006;24:4783-4791.
3. Sherman ME, Bur ME, Kurman RJ. p53 in endometrial cancer and its putative precursors: Evidence for diverse pathways of tumorigenesis. Hum Pathol. 1995;26:1268-1274.
4. Minamoto T, Mai M, Ronai Z. K-ras mutation: early detection in molecular diagnosis and risk assessment of colorectal, pancreas, and lung cancersVa review. Cancer Detect Prev. 2000;24:1-12.
5. Enomoto T, Inoue M, Perantoni AO, et al. K-ras activation in premalignant and malignant epithelial lesions of the human uterus. Cancer Res. 1991;51:5308-5314.
6. Keating GM. Panitumumab: A review of its use in metastatic colorectal cancer. Drugs. 2010;70:1059-1078.
7. Banck MS, Grothey A. Biomarkers of resistance to epidermal growth factor receptor monoclonal antibodies in patients with metastatic colorectal cancer. Clin Cancer Res. 2009;15: 7492-7501.
8. Amado RG, Wolf M, Peeters M, et al.Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:1626-1634. E-pub Mar 3, 2008.
9. Swisher EM, Peiffer-Schneider S, Mutch DG, et al. Differences in patterns of TP53 and KRAS2 mutations in a large series of endometrial carcinomas with or without microsatellite instability. Cancer. 1999;85:119-126.
10. Lax SF, Kendall B, Tashiro H, et al. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer. 2000;88:814-824.
11. Semczuk A, Berbe( H, Kostuch M, et al. K-ras gene point mutations in human endometrial carcinomas: correlation with clinicopathological features and patients' outcome. J Cancer Res Clin Oncol. 1998;124:695-700.
12. Byron SA, Gartside M, Powell MA, et al. FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features. PLoS One. 2012;7:e30801. Doi:10.1371/journal.pone.0030801.
13. Stewart CJR, Amanuel B, Grieu F, et al. KRAS mutation and microsatellite instability in endometrial adenocarcinomas showing MELF-type myometrial invasion. J Clin Pathol. 2010;63:604-608.
14. Cuatrecasas M, Villanueva A, Matias-Guiu X, et al. K-ras mutations in mucinous ovarian tumor. A clinicopathologic and molecular study of 95 cases. Cancer. 1997;79:1581-1586.
15. Enomoto T, Weghorst CM, Inoue M, et al. K-ras activation occurs frequently in mucinous adenocarcinomas and rare in other common epithelial tumors of the human ovary. Am J Pathol. 1991;139:777-785.
16. Schonleben F, Qiu W, Bruckman KC, et al. Braf and Kras gene mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/IPMC) of the pancreas. Cancer Lett. 2007;249:242-248.
17. Araki T, Shimizu K, Nakamura K, et al. Usefulness of peptide nucleic acid (PNA)-clamp smart amplification process version 2 (SmartAmp2) for clinical diagnosis of KRAS codon12 mutations in lung adenocarcinoma. Comparison of PNA-clamp SmartAmp2 and PCR-related methods. J Mol Diagn. 2010;12:118-124.
18. Bansal N, Yendluri V, Wenham RM. The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control. 2009;16:8-13.
19. Pappa KI, Choleza M, Markaki S, et al. Consistent absence of BRAF mutations in cervical and endometrial cancer despite KRAS mutation status. Gynecol Oncol. 2006;100:596-600. E-pub Oct 26, 2005.
20. Zighelboim I, Goodfellow PJ, Schmidt AP, et al. Differential methylation hybridization array of endometrial cancers reveals two novel cancer-specific methylation markers. Clin Cancer Res. 2007;13:2882-2889.
21. Nagasaka T, Goel A, Notohara K, et al. Methylation pattern of the O6-methylguanine-DNA methyltransferase gene in colon during progressive colorectal tumorigenesis. Int J Cancer. 2008;122:2429-2436.
22. Esteller M, Herman JG. Generating mutations but providing chemosensitivity: The role of O6-methylguanine DNA methyltransferase in human cancer. Oncogene. 2004;23:1-8.
23. Esteller M, Toyota M, Sanchez-Cespedes M, et al. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in k-ras in colorectal tumorigenesis. Cancer Res. 2000;60:2368-2371.
24. Temkin SM, Fleming G. Current treatment of metastatic endometrial cancer. Cancer Control. 2009;16:38-45.
25. Chon HS, HuW, Kavanagh JJ. Targeted therapies in gynecologic cancers. Curr Cancer Drug Targets. 2006;6:333-363.